- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Adherence varies across market segments
State-level data shows potential cost savings when patients follow regimens
The U.S. healthcare system could avoid hundreds of millions of dollars in medical costs if medication adherence rates improved, according to a CVS Caremark report.
The 2013 State of the States: Adherence Reportreports potential cost-savings within each state by examining medication adherence rates and the use of generic drugs across four common health conditions: diabetes, hypertension, dyslipidemia (high cholesterol), and depression. The potential cost-savings among the states range from $19 million to $2.1 billion based on state member characteristics. The report looked at health plans, employer-sponsored plans, and Medicare Part D prescription drug plans (PDPs).
“These projections are broken down on a state-by-state basis in the report to call attention to the savings that could be achieved by encouraging people to stay on their medications and to consider generic alternatives when they are available,” Christine Cramer, CVS Caremark spokesperson says.
There are many factors that influence adherence, including demographics and access to pharmacy services, which are also highlighted in the report at the state-level, according to Cramer.
Across all market segments, patients with depression generally had the lowest adherence rates, while patients with hypertension were most adherent. Medicare beneficiaries had the highest adherence rates across the three groups.
“There are costs that are avoided when people stay on medication-reduced frequency in trips to the emergency room and in-patient hospital stays, to name a couple of examples-these add costs to the system,” says Cramer. “Getting patients to take their medications can help people remain healthy and reduce costs.”
Adherence rates fluctuate across populations, regions and markets.
Concrete approaches such as designing new packaging and pill boxes that help simplify medication regimens, better medication education and coordination in post-operative care to help reduce readmissions, and pharmacy-based counseling programs can help.
As one element of its research, CVS Caremark has been working in a multi-year collaboration with Brigham and Women’s Hospital to research pharmacy claims data in order to better understand the factors that influence medication adherence.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More
